GlaxoSmithKline PLC (NYSE:GSK)‘s stock had its “neutral” rating restated by investment analysts at J P Morgan Chase & Co in a research report issued on Thursday.

Several other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a research report on Monday, April 17th. TheStreet upgraded shares of GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research note on Friday, May 19th. BNP Paribas upgraded shares of GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating and dropped their price objective for the company from $45.58 to $37.20 in a research note on Wednesday, April 5th. Exane BNP Paribas upgraded shares of GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating in a research note on Wednesday, April 5th. Finally, ValuEngine lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $45.25.

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded up 0.21% during midday trading on Thursday, hitting $42.61. The stock had a trading volume of 1,671,586 shares. The firm has a 50 day moving average price of $43.56 and a 200-day moving average price of $41.27. The stock has a market cap of $104.10 billion, a PE ratio of 47.98 and a beta of 1.04. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $45.58.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.62 earnings per share for the quarter, meeting the consensus estimate of $0.62. GlaxoSmithKline PLC had a net margin of 5.48% and a return on equity of 113.31%. The business had revenue of $9.23 billion during the quarter, compared to analysts’ expectations of $9.09 billion. Equities analysts predict that GlaxoSmithKline PLC will post $2.82 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 13th. Shareholders of record on Friday, May 12th will be issued a dividend of $0.483 per share. This represents a $1.93 dividend on an annualized basis and a dividend yield of 4.54%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Wednesday, May 10th. GlaxoSmithKline PLC’s dividend payout ratio is 233.74%.

COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/13/glaxosmithkline-plc-gsk-rating-reiterated-by-j-p-morgan-chase-co.html.

Several hedge funds have recently added to or reduced their stakes in GSK. FMR LLC boosted its stake in GlaxoSmithKline PLC by 11.7% in the first quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company’s stock worth $996,452,000 after buying an additional 2,482,009 shares during the period. Thrivent Financial For Lutherans raised its position in shares of GlaxoSmithKline PLC by 87,023.5% in the first quarter. Thrivent Financial For Lutherans now owns 1,373,066 shares of the pharmaceutical company’s stock worth $57,884,000 after buying an additional 1,371,490 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of GlaxoSmithKline PLC by 42.7% in the first quarter. Renaissance Technologies LLC now owns 4,402,100 shares of the pharmaceutical company’s stock worth $185,593,000 after buying an additional 1,316,600 shares in the last quarter. Bank of America Corp DE raised its position in shares of GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after buying an additional 934,928 shares in the last quarter. Finally, Fisher Asset Management LLC raised its position in shares of GlaxoSmithKline PLC by 4.7% in the second quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock worth $540,483,000 after buying an additional 564,519 shares in the last quarter. 8.96% of the stock is currently owned by institutional investors and hedge funds.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.